ArticleOncology letters2025

Comparative efficacy and safety of first‑line PD‑1/PD‑L1 inhibitors in immunotherapy for non‑small cell lung cancer: A network meta‑analysis.

Liyan Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.